Teva Pharmaceutical Industries Limited Setting The Table For Earnings


International Business Machines (IBM)'s Expected EPS Growth Clearing Whole Picture- Teva Pharmaceutical

However a year ago for the same quarter the company has reported $1.2 EPS. Teva Pharmaceutical Industries's quarterly revenue was up 33.0% compared to the same quarter previous year. The stock remained 2.27% volatile for the week and 2.13% for the month. Inc. bought a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at about $577,310,000. CKW Financial Group acquired a new position in Teva Pharmaceutical Industries during the third quarter worth approximately $168,000. Quarterly performance of the company shows declining momentum of -2.30% while its last one month trend is negative with -3.59%. Quantbot Technologies LP boosted its stake in Teva Pharmaceutical Industries by 16.3% in the third quarter. Vetr's price target points to a potential upside of 4.34% from the stock's current price. Advisory Services Network LLC purchased a new position in Teva Pharmaceutical Industries during the first quarter valued at approximately $163,000. Barrow Hanley Mewhinney & Strauss LLC now owns 32,455,432 shares of the company's stock valued at $1,176,510,000 after buying an additional 5,884,444 shares during the period.

Hedge funds and other institutional investors have recently modified their holdings of the stock.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) traded up 1.4911% during mid-day trading on Tuesday, hitting $31.2491. Cwm Llc sold 278,133 shares as Acacia Resh Corp (ACTG)'s stock rose 1.25%. Teva Pharmaceutical Industries Ltd has a 12 month low of $30.22 and a 12 month high of $56.44. The company has a market cap of $31.73 billion, a PE ratio of 446.57 and a beta of 0.58.

The share price of Teva Pharmaceutical Industries Limited (NYSE:TEVA) was down -1.12% during the last trading session, with a day high of 31.31. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.36 by $0.02. First quarter revenue totaled $5.6 billion, up 17% from the corresponding quarter of 2016 due to the Actavis acquisition. Return on Equity (ROE) stands at 0.2% and Return on Investment (ROI) of 1.1 percent. During the same period past year, the business earned $1.32 EPS. Equities analysts anticipate that Teva Pharmaceutical Industries Ltd will post $4.82 earnings per share for the current fiscal year. SOL Capital Management CO raised its position in shares of Teva Pharmaceutical Industries by 5.8% in the third quarter. If you are accessing this report on another publication, it was illegally copied and reposted in violation of USA & worldwide copyright & trademark laws.

The company is expected to report earnings of $1.03 a share for the next quarter.

Several research firms have recently issued reports on TEVA. At recent closing price of $7.63, VER has a chance to add $2.19 or 28.7% in 52 weeks, based on mean target price ($9.82) placed by analysts.The analyst consensus opinion of 2.6 looks like a hold.

Analysts await Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to report earnings on May, 11. The original version of this report can be read at Mizuho reaffirmed a "neutral" rating and set a $27.00 price objective (down from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Tuesday, February 7th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and fourteen have issued a buy rating to the stock. Price to sales ratio was 1.84 while 62.40% of stock was owned by Institutional investors.

Finally, Barclays PLC dropped their price objective on Teva Pharmaceutical Industries from $46.00 to $38.00 and set an "equal weight" rating for the company in a research note on Tuesday, January 31st. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines.

Generic medicine sales of $3.1 billion grew 24% and comprised 54% of total sales, up from the 51% chunk it represented in the year-earlier period. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Ultimas noticias